GENELUX CORPORATION -

Genelux Corporation Reports Third Quarter 2024 Financial Results and Provides General Business Updates

14 Nov 2024 15:05:00 By Nasdaq GlobeNewswire

Genelux Corporation Announces First Patient Dosed in Phase 2 Trial Evaluating Systemic Therapy with Olvi-Vec in Non-Small Cell Lung Cancer

22 Oct 2024 15:01:09 By Nasdaq GlobeNewswire

Genelux Corporation to Participate in the 2024 Maxim Healthcare Virtual Summit

09 Oct 2024 15:15:00 By Nasdaq GlobeNewswire

Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference

03 Sep 2024 15:01:00 By Nasdaq GlobeNewswire

Genelux Corporation Reports Second Quarter 2024 Financial Results and Provides General Business Updates

14 Aug 2024 15:05:55 By Nasdaq GlobeNewswire

Genelux Corporation to Participate in Fireside Chat at BTIG’s Virtual Biotechnology Conference 2024

30 Jul 2024 06:00:00 By Nasdaq GlobeNewswire

Genelux Corporation Announces Pricing of Approximately $27.5 Million Underwritten Offering of Common Stock and Accompanying Warrants

24 May 2024 07:00:00 By Nasdaq GlobeNewswire

Genelux Corporation Announces Proposed Public Offering of Common Stock and Warrants

23 May 2024 15:01:00 By Nasdaq GlobeNewswire

Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business Updates

09 May 2024 15:25:23 By Nasdaq GlobeNewswire

Genelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

01 Apr 2024 06:00:00 By Nasdaq GlobeNewswire

Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer

27 Nov 2023 06:00:00 By Nasdaq GlobeNewswire

Genelux Corporation Reports Third Quarter 2023 Financial Results and Provides General Business Updates

14 Nov 2023 16:50:38 By Nasdaq GlobeNewswire

Genelux Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

14 Sep 2023 06:00:00 By Nasdaq GlobeNewswire

Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference

07 Sep 2023 15:01:00 By Nasdaq GlobeNewswire

Genelux Corporation Announces New Chief Financial Officer

28 Aug 2023 06:00:00 By Nasdaq GlobeNewswire

Genelux Corporation Reports Second Quarter 2023 Financial Results and Provides General Business Updates

14 Aug 2023 06:00:00 By Nasdaq GlobeNewswire

Genelux Corporation to Participate in Fireside Chat at BTIG’s Virtual Biotechnology Conference 2023

02 Aug 2023 15:00:00 By Nasdaq GlobeNewswire

Genelux Corporation Strengthens Senior Management and Clinical Team with Promotions and New Hires

20 Jul 2023 15:45:00 By Nasdaq GlobeNewswire

Genelux Corporation Announces Publication of Phase I Trial Results of Intrapleural Administration of Olvi-Vec in Patients with Malignant Pleural Effusion from Mesothelioma, Lung or Breast Cancers in Frontiers in Immunology

10 Jul 2023 06:00:00 By Nasdaq GlobeNewswire

Genelux Corporation and TVAX Biomedical, Inc. announce the issuance of a United States patent covering the combination of an adoptive T cell therapy/oncolytic viral cancer treatment that is exclusively licensed to V2ACT Therapeutics™, LLC

29 Jun 2023 06:00:00 By Nasdaq GlobeNewswire